Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Sernova Corp (SVA.TO)

Sernova Corp (SVA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stocks in play: Sernova Biotherapeutics Baystreet - Wed Mar 4, 8:44AM CST

Today announced financing transactions totaling $7.1 million, significantly strengthening the Company's ...

SVA.TO : 0.1650 (+17.86%)
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval Newsfile - Wed Mar 4, 6:04AM CST

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine...

SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)
Sernova Biotherapeutics Announces Warrant Amendments Newsfile - Fri Feb 20, 6:02AM CST

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company...

SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)
Upcoming Meeting Dates - February 2, 2026 Newsfile - Sun Feb 1, 11:04PM CST

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

ESG.TO : 49.56 (+0.38%)
CAPR.CN : 0.1150 (-4.17%)
OGI.TO : 1.91 (+2.14%)
BTT.VN : 0.075 (-6.25%)
CRCL.CN : 0.2450 (unch)
RGI.VN : 0.015 (unch)
MEK.VN : 0.040 (-11.11%)
MARY.CN : 0.0700 (unch)
SFI.TO : 0.2750 (unch)
ENEV.VN : 0.015 (unch)
URZ.VN : 0.340 (+3.03%)
ZONE.VN : 0.020 (+33.33%)
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts Newsfile - Thu Nov 13, 2025

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine...

SVA.TO : 0.1650 (+17.86%)
Stocks in play: Sernova Biotherapeutics Baystreet - Wed Oct 1, 2025

Today announced that it has signed debt-to-equity conversion agreements with vendors to convert approximately ...

SVA.TO : 0.1650 (+17.86%)
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang Newsfile - Wed Oct 1, 2025

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused...

SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes GlobeNewswire - Wed Jul 9, 2025

ELDN : 2.57 (+2.48%)
SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)
Sernova Appoints Jonathan Rigby as Interim Chair GlobeNewswire - Mon Jun 2, 2025

SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)
Chair of Sernova Biotherapeutics Resigns GlobeNewswire - Sun May 25, 2025

SVA.TO : 0.1650 (+17.86%)
SEOVF : 0.1218 (+18.37%)

Barchart Exclusives

Down 24% in 2026, Should You Buy the Dip in Oracle Stock? Barchart - 20 minutes ago
With soaring AI investments, rising debt, and legal scrutiny swirling around Oracle, is the stock’s 2026 slide a golden buying opportunity or a red flag? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot